Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
University of California, Irvine - Chao Family Comprehensive Cancer Center, Orange, California Georgia Cancer Center at Augusta University, Augusta, Georgia Beth Israel Deaconess Medical Center, Boston, Massachusetts Duke Cancer Institute, Durham, North Carolina University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Fred Hutchinson Cancer Center, Seattle, Washington